Soluble TWEAK and PTX3 in nondialysis CKD patients: Impact on endothelial dysfunction and cardiovascular outcomes

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 785-792

  Yilmaz, Mahmut Ilker ^a   Sonmez, Alper ^a   Ortiz, Alberto ^a   Saglam, Mutlu ^a   Kilic, Selim ^a   Eyileten, Tayfun ^a   Caglar, Kayser ^a   Oguz, Yusuf ^a   Vural, Abdulgaffar ^a   Çakar, Mustafa ^a   Egido, Jesus ^a   Altun, Battal ^b   Yenicesu, Mujdat ^a   Blanco Colio, Luis Miguel ^a   Carrero, Juan Jesus ^c,d,e  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b 28400 Madrid   (Spain)

^c Divisions of Baxter Novum and Renal Medicine   (Sweden)

^d Centre for Molecular Medicine   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; PENTRAXIN 3; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTIMA; MALE;

ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; TUMOR NECROSIS FACTORS; TUNICA INTIMA; TUNICA MEDIA; VASODILATION;

EID: 79955566226     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09231010     Document Type: Article

References (42)

1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wet-zels JF, Rosendaal FR, Dekker FW: Cardiovascular and non-cardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789, 2009
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 351: 1296-1305, 2004
3. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62: 1402-1407, 2002
4. Zoccali C: Endothelial dysfunction and the kidney: Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 17: S61-S63, 2006
5. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease: What have we learned in 10 years? Semin Dial 23: 498-509, 2010
6. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev 7: 411-425, 2008
7. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM: Soluble TWEAK plasma levels as a novel biomarker of endo-thelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 4: 1716-1723, 2009
8. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, Marron B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM: Additive effects of soluble TWEAK and inflammation on mortality in hemodialy-sis patients. Clin J Am Soc Nephrol 4: 110-118, 2009
9. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, Mantovani A: The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: Interplay with cellular innate immunity. Immunol Rev 227: 9-18, 2009
10. Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366, 2005
11. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A: Inducible expression of PTX3, a new member of the pen-traxin family, in human mononuclear phagocytes. Blood 84: 3483-3493, 1994
12. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, Mantovani A: Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175: 221-228, 2004
13. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, Axelsson J, Alvestrand A, Stenvinkel P, Lind-holm B, Suliman ME: Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2: 889-897, 2007
14. Suliman ME, Qureshi AR, Carrero JJ, Barany P, Yilmaz MI, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: The long pentraxin PTX-3 in prevalent hemodialysis patients: Associations with comorbidities and mortality. QJM 101: 397-405, 2008
15. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, Tong M, Heimburger O, Barany P, Alvestrand A, Lindholm B, Stenvinkel P: Novel links between the long pentraxin 3, endothelial dysfunction, and albumin-uria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 3: 976-985, 2008
16. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, Ortiz A, Meilhac O, Egido J: Identification of soluble tumor necrosis factor-like weak inducer of apo-ptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-922, 2007
17. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK: Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: E10-E18, 2002
18. Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Ca-glar K, Eyileten T, Sonmez A, Oguz Y, Vural A, Yenicesu M, Axelsson J: Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol 31: 214-221, 2010
19. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42[Suppl 3]: S1-S202, 2004
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
21. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115, 1992
22. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R: The long pentraxin PTX3 in vascular pathology. Vasc Pharmacol 45: 326-330, 2006
23. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T: Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161-167, 2007
24. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A, Lipid Assessment Trial Italian Network I: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354, 2004
25. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL: Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28: 925-931, 2008
26. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B, Peri G, Doni A, Vago L, Botto M, De Santis R, Carminati P, Siracusa G, Altruda F, Vecchi A, Romani L, Mantovani A: Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420: 182-186, 2002
27. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, Iwanari H, Sagara M, Tanaka T, Ha-makubo T, Kodama T, Naito M: Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215: 48-55, 2008
28. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K: Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197: 368-374, 2008
29. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL: Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708, 2009
30. Augst AD, Ariff B, Mc, GTSA, Xu XY, Hughes AD: Analysis of complex flow and the relationship between blood pressure, wall shear stress, and intima-media thickness in the human carotid artery. Am J Physiol Heart Circ Physiol 293: H1031-H1037, 2007
31. Richter B, Rychli K, Hohensinner PJ, Berger R, Mortl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hulsmann M, Niessner A: Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 213: 545-548, 2010
32. Jager KJ, Stel VS, Zoccali C, Wanner C, Dekker FW: The issue of studying the effect of interventions in renal replacement therapy: To what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant 25: 3836-3839, 2010
33. Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. Clin J Am Soc Nephrol 4[Suppl 1]: S49-S55, 2009
34. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 29: 2061-2068, 2009
35. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, Ortiz A: Cytokine cooperation in renal tubular cell injury: The role of TWEAK. Kidney Int 70: 1750-758, 2006
36. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A: Tweak induces proliferation in renal tubular epithelium: A role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 13: 3329-3342, 2009
37. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM: Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke 37: 2044-2053, 2006
38. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM: The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207: 103-110, 2009
39. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O: Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 30: 1253-1262, 2010
40. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: How can we treat it? Blood Purif 26: 291-299, 2008
41. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyi-leten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P: Effect of renin angio-tensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 4: 535-541, 2009
42. Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM: Combined therapy with renin-ang-iotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: Effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5: 1174-1181, 2010